Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02720185 · ClinicalTrials.gov registry record · Phase 2
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
A Phase 2 study, sponsored by University of Wisconsin, Madison.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT02720185 is a Phase 2 study that was terminated before completion, run by University of Wisconsin, Madison. The registered enrollment target is 5 participants.
The verdict
NCT02720185, a Phase 2 study, was terminated before completion, sponsored by University of Wisconsin, Madison.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety and tolerability of dasatinib in patients with operable TNBC 2. To explore potential intracellular mechanisms which impact dasatinib effect on cellular localization of EGFR in operable TNBC. 3. To examine the pathologic complete response (pCR) rates to standard neoadjuvant chemotherapy in nEGFR+ TNBC 4. To examine breast cancer recurrence rates and patterns of metastatic recurrent in nEGFR+ TNBC
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Dasatinib
- PROCEDURE Conventional Surgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-05-03 |
| Est. Completion | 2022-02-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02720185
The ClinicalTrials.gov registry entry for NCT02720185 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT02720185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02720185 about?
NCT02720185 is a clinical study titled "Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR". Primary Objective: To determine if dasatinib, an inhibitor of the Src family kinases, can prevent the nuclear translocation of the epidermal growth factor receptor (EGFR) in Stage I-III, nuclear EGFR positive, triple negative breast cancers (TNBC). Secondary Objectives: 1. To examine the safety a...
What is the current status of trial NCT02720185?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2017-05-03. Estimated completion is 2022-02-08.
What interventions are being tested in trial NCT02720185?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Dasatinib (DRUG), Conventional Surgery (PROCEDURE).
Who is sponsoring clinical trial NCT02720185?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.